VGPRVery Good Partial Remission
References in periodicals archive ?
Overall, we found that the ORR of patients treated with bortezomib combination regimens was 95.5% (85/89) including 52.8% (47/89) CR, 16.8% (15/89) VGPR, and 23.6% (27/89) PR.
Multiple prospective studies of newly diagnosed myeloma patients demonstrated either a longer EFS and/or a better OS in patients who achieved CR or at least VGPR, after a single [101,102] or tandem ASCT [103-106].
Briefly, complete response (CR) was defined as an undetectable level of serum M-protein and [less than or equal to] 5% bone marrow plasma cells (BMPCs), VGPR was defined as a reduction in serum M-protein by at least 90% of the initial value, and partial response (PR) was defined as a reduction in M-protein by approximately 50-90%.
VGPR corresponds to serum monoclonal immunoglobulin decreased by 90% and to urinary immunoglobulin <100 mg/24 H.
(35) The benefit was, however, limited to patients not achieving at least a very good partial response (VGPR) and a meta-analysis of 6 RCTs showed increased toxicity with no significant difference in overall survival (OS).
Vega Biofuel Incorporated (PINKSHEETS: VGPR), a company which is in the process of building a manufacturing plant that, when finished, will manufacture biocoal from timber waste using a technology called torrefaction, has completed an interim funding package.
Additionally, while efficacy was not the primary endpoint of the Phase I study, it was observed that out of 10 evaluable subjects, two subjects had stable disease for over four months and one patient achieved a very good partial response, or VGPR. In addition, results from preclinical studies demonstrated that SK2 is overexpressed in multiple myeloma cell lines and in human multiple myeloma specimens and plays a critical role in myeloma cell growth, proliferation and survival.
Stringent complete response (sCR) was reported in 2.8 percent of patients, very good partial response (VGPR) was reported in 9.4 percent of patients, and partial response (PR) was reported in 17 percent of patients.1 These efficacy results were based on ORR as determined by the Independent Review Committee assessment using IMWG (International Myeloma Working Group) criteria and the range for median duration of response.
Responses to treatment and disease status were assessed with the use the European Group for Blood and Marrow Transplantation criteria, [sup][21] and a very good partial response (VGPR) was defined according to the International Uniform Response Criteria for Multiple Myeloma.
Lenalidomide provides the most benefit in those who fail to achieve CR or very good partial response (VGPR), by IMWG criteria, after ASCT.
"We continue to be encouraged by the quality and durability of response with zanubrutinib in the treatment of patients with Waldenstrom macroglobulinemia, or WM, particularly with the observation that 43 percent of the evaluable patients achieved a very good partial response, or VGPR. Additionally, the safety results from the combined experience in four ongoing monotherapy trials demonstrate that zanubrutinib was generally well-tolerated," commented Jane Huang, M.D., Chief Medical Officer, Hematology, at BeiGene.